TransMedics Group, Inc.TMDX
Health Care · Health Care Equipment & Services · NASDAQ · United States · transmedics.com
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that replicates near-physiologic conditions for donor organs outside of the human body.
Key ratios
Operating cash flow growth
26.6%TTM
2025
295.1%
EPS growth
98.9%TTM
2025
382.5%
FCF / Sales
22.1%2025
2024
-18.3%2023
-68.2%
Net margin
22.7%TTM
2025
31.4%2024
8.0%2023
-10.4%
ROA
4.3%TTM
2025
7.3%2024
3.1%2023
-0.2%
ROE
36.3%TTM
2025
54.2%2024
19.4%2023
-15.4%
Revenue growth
37.1%2025
2024
82.7%2023
158.5%
Track TMDX in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer